Prothena slides after called ‘next big biotech blow-up’ by Kerrisdale

Shares of Prothena are weak in early trading after Kerrisdale Capital called the company “The Next Big Biotech Blow-Up” in a newly-issued short report. “In the Phase 1/2 trial, NEOD001 failed to achieve meaningful clinical response, durable response, dose response, control over catastrophic events, or any apparent benefit at all. The Phase 2b and Phase 3 trials will be no different,” Kerrisdale contends in its report.